CD8型
CD28
肺癌
医学
细胞毒性T细胞
免疫学
CD38
癌症
T细胞
PD-L1
癌症研究
内科学
免疫系统
免疫疗法
生物
体外
生物化学
遗传学
干细胞
川地34
作者
Alice Oliffson Kamphorst,Rathi Narayana Pillai,Shu Yang,Tahseen H. Nasti,Rama S. Akondy,Andreas Wieland,Gabriel Sica,Ke Yu,Lydia Koenig,Nikita T. Patel,Madhusmita Behera,Hong Gyun Wu,Megan M. McCausland,Zhengjia Chen,Chao Zhang,Fadlo Raja Khuri,Taofeek Kunle Owonikoko,Rafi Ahmed,Suresh S. Ramalingam
标识
DOI:10.1073/pnas.1705327114
摘要
Significance Therapies that harness the immune system have recently been approved for cancer treatment. Identification of biomarkers to monitor or predict patients’ responses to immunotherapies would help guide treatment decisions. Herein we analyzed changes in peripheral blood T cells from lung cancer patients receiving immunotherapy blocking the PD-1 inhibitory pathway. We detected CD8 T-cell responses following treatment in most patients. In addition, our data suggest that an increase in proliferation of PD-1+ CD8 T cells in the blood within 4 wk of treatment initiation may be associated with positive clinical outcome. Our analysis provides valuable insights into cancer patients’ responses to PD-1–targeted therapies and warrant further studies on peripheral blood biomarkers.
科研通智能强力驱动
Strongly Powered by AbleSci AI